Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3533710 | 0.89 | DRD2 (0.39) | DRD2DRD3PNMTMAPK1CHRM2 | |
| SCHEMBL397802 | 0.88 | — | — | |
| SCHEMBL9500822 | 0.88 | PNMT (0.41) | DRD2DRD3PNMTMAPK1 | |
| Hydrochloric Acid SCHEMBL12485568 | 0.86 | DRD2 (0.40) | DRD2DRD3PNMTMAPK1 | |
| Hydrochloric Acid SCHEMBL22395725 | 0.86 | DRD2 (0.40) | DRD2DRD3PNMTMAPK1 | |
| SCHEMBL3725694 | 0.83 | DRD2 (0.38) | DRD2DRD3PNMTMAPK1 | |
| Urea SCHEMBL21906543 | 0.79 | PNMT (0.40) | DRD2DRD3PNMTMAPK1 | |
| SCHEMBL25159158 | 0.77 | DRD2 (0.48) | DRD2DRD3MAPK1 | |
| Ammonia Solution, Strong SCHEMBL2460630 | 0.77 | DRD2 (0.48) | DRD2DRD3MAPK1 | |
| Bromide SCHEMBL6150945 | 0.77 | DRD2 (0.48) | DRD2DRD3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230146129-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11566026-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220213090-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-06-23 | — | — | US | disclosed |
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210107900-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
| US-20210002276-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-01-07 | — | — | US | disclosed |
| US-20200325115-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-10-15 | — | — | US | disclosed |
| US-10800768-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190225601-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-07-25 | — | — | US | disclosed |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180179179-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179201-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| EP-2049548-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | DRD2 2789/4885DRD3 3417/4885PNMT 1698/4885 |
| US-20220213090-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | DRD2 2789/4885DRD3 3417/4885PNMT 1698/4885 |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | DRD2 2789/4885DRD3 3417/4885PNMT 1698/4885 |
| US-20200325115-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | DRD2 2789/4885DRD3 3417/4885PNMT 1698/4885 |
| US-20210107900-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | DRD2 2789/4885DRD3 3417/4885PNMT 1698/4885 |
| US-20190225601-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | DRD2 2789/4885DRD3 3417/4885PNMT 1698/4885 |
| US-11566026-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | DRD2 2789/4885DRD3 3417/4885PNMT 1698/4885 |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | DRD2 2789/4885DRD3 3417/4885PNMT 1698/4885 |
| US-20230146129-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | DRD2 2789/4885DRD3 3417/4885PNMT 1698/4885 |
| US-20180179179-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | DRD2 2789/4885DRD3 3417/4885PNMT 1698/4885 |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | DRD2 2789/4885DRD3 3417/4885PNMT 1698/4885 |
| US-20210002276-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | DRD2 2789/4885DRD3 3417/4885PNMT 1698/4885 |
| US-20180179201-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | DRD2 2789/4885DRD3 3417/4885PNMT 1698/4885 |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | DRD2 2789/4885DRD3 3417/4885PNMT 1698/4885 |
| US-10800768-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | DRD2 2789/4885DRD3 3417/4885PNMT 1698/4885 |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | DRD2 2789/4885DRD3 3417/4885PNMT 1698/4885 |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | HRH3, HRH4, HRH2 | DRD2 874/4885DRD3 668/4885PNMT 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.